Search results
FDA presses pause on trial for OTC version of anti-impotence drug Cialis
Reuters via Yahoo News· 2 years agoPARIS/LONDON (Reuters) -The U.S. health regulator has put on hold a trial designed to evaluate...
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
Zacks via Yahoo Finance· 1 year agoUnited Therapeutics‘ UTHR fourth-quarter 2022 adjusted earnings of $2.67 per share missed the Zacks...
Eli Lilly Slashes Profit Outlook After 'Significantly' Missing Second-Quarter Forecasts
Investor's Business Daily· 2 years agoEli Lilly slashed its 2022 earnings outlook Thursday after significantly missing second-quarter...
Eli Lilly and Company (LLY) Q2 2022 Earnings Call Transcript
Motley Fool· 2 years agoImage source: The Motley Fool. Eli Lilly and Company (NYSE: LLY) Q2 2022 Earnings Call Aug 04, 2022,...
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
Zacks via Yahoo Finance· 2 years agoUnited Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same....
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoHigher demand for its key drugs is likely to have offset generic competition for several other drugs...
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Zacks via Yahoo Finance· 2 years agoFor new and old investors, taking full advantage of the stock market and investing with confidence...
FDA Approves First Erectile Dysfunction Gel That Doesn't Require a Prescription
Futurism via Yahoo News· 11 months agoThose looking for a good time but having a little trouble downstairs may finally have the cure that...
The nutritional supplements industry is booming, but experts warn it presents risks
The Hill via Yahoo News· 2 years agoStory at a glance In the United States, all supplements — defined as minerals, vitamins, probiotics...
The 7 Best Pharma Stocks to Buy Now
InvestorPlace via Yahoo Finance· 2 years agoWith the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry...
